In the first week of November, BioAgilytix Labs, LLC, a portfolio company of Riverside Partners, purchased Cambridge Biomedical. Both Cambridge and BioAgilytix are contract research organizations (CROs) that develop novel therapeutic biologics and biosimilars, specializing in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, […]
Pamplona Capital Management was on the hunt for a contract research organization (CRO). After missing out on PPD, the PE firm bagged publicly traded PAREXEL for $5.2 billion.
We’ve documented the increase in biotechnology acquisitions and license deals by pharmaceutical companies in previous posts. But the impact of pharma’s move away from in-house R&D has benefited other sectors of the healthcare industry, particularly clinical research organizations (CROs). For those outside the technology side of healthcare, CROs provide outsourced research services to the pharmaceutical, […]